Goodwin advised Tay on the agreement. Tay entered into a license agreement with VYNE Therapeutics, under which VYNE obtained exclusive rights to Tay’s oral BET inhibitor, TAY-B2...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here